AOST1321
Regimen
- Experimental
- Denosumab (RANKL inhibitor) monotherapy
- Control
- None (single-arm, response/DCR primary)
Population
Pediatric/AYA recurrent or refractory osteosarcoma, two cohorts (measurable disease and surgically rendered NED)
Key finding
Denosumab monotherapy failed as a single-agent anti-tumor drug in osteosarcoma despite strong preclinical rationale in the bone microenvironment. Retains role only as skeletal-related-event prophylaxis. PMID 41159913 indexed 2026 (Janeway KA, Clin Cancer Res); confirm exact year if citing.
Source: PMID 41159913